What is Iovance Biotherapeutics, Inc.'s D&A?

Iovance Biotherapeutics, Inc. (IOVA) reported D&A of $2.82M in Q1 2026.

How has Iovance Biotherapeutics, Inc.'s D&A changed year-over-year?

Iovance Biotherapeutics, Inc.'s D&A increased by 9.8% year-over-year, from $2.57M to $2.82M.

What is the long-term trend for Iovance Biotherapeutics, Inc.'s D&A?

Over 4 years (2021 to 2025), Iovance Biotherapeutics, Inc.'s D&A has grown at a 42.1% compound annual growth rate (CAGR), from $3.11M to $12.68M.

Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.

Iovance Biotherapeutics, Inc. IOVA D&A

D&A at other companies

Bristol-Myers SquibbBMY

$594M-41.3%

ImmunomeIMNM

$603K-1.3%

Nuvation BioNUVB

$536K+72.9%

ImmunityBio, Inc.IBRX

$4.38M+14.4%

Immunovant, Inc.IMVT

$96K-11.9%

Viridian Therapeutics, Inc.VRDN

$121K+3.4%

Segments

By segment

See full

Single Reportable$8.54M+5.9%

Other financials

Income statement

See full

Revenue$71.4M+44.8%

Gross profit$28.9M+338%

Operating income-$81.0M+33.1%

Net income-$79.0M+32.0%

EPS (diluted)-$0.19+47.2%

Balance sheet

See full

Cash & equivalents$196.5M+14.5%

Total debt$46.8M-11.3%

Total equity$721.8M-6.0%

Total assets$925.7M-4.2%

Cash flow

See full

Operating cash flow-$72.1M+30.5%

CapEx$6.6M+6.4%

Free cash flow-$78.7M+28.4%

Valuation

See full

Market cap$1.98B+32.4%

Enterprise value$1.83B+33.2%

P/S6.9×-0.1×

Profitability

See full

Gross margin36.7%+4.1pp

Operating margin-127.2%-31.0pp

Net margin-123.9%-28.4pp

FCF margin-106.8%-27.5pp

Returns & leverage

See full

Return on equity-47.5%-3.7pp

Debt / equity0.1×0.0×

Current ratio3.6×-0.6×

Where this comes from

Reported directly by Iovance Biotherapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.

The official record: Iovance Biotherapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Iovance Biotherapeutics, Inc.'s d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Iovance Biotherapeutics, Inc.'s D&A?: Iovance Biotherapeutics, Inc. (IOVA) reported D&A of $2.82M in Q1 2026.
How has Iovance Biotherapeutics, Inc.'s D&A changed year-over-year?: Iovance Biotherapeutics, Inc.'s D&A increased by 9.8% year-over-year, from $2.57M to $2.82M.
What is the long-term trend for Iovance Biotherapeutics, Inc.'s D&A?: Over 4 years (2021 to 2025), Iovance Biotherapeutics, Inc.'s D&A has grown at a 42.1% compound annual growth rate (CAGR), from $3.11M to $12.68M.
What does D&A mean?: Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.